Radiographic evaluation of the pleural fluid accumulation rate after pneumonectomy.

Clin Imaging

Department of Thoracic Surgery, University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address:

Published: October 2015

Purpose: Understanding the radiographic appearance and normal rate of fluid accumulation after pneumonectomy is important in order to detect postoperative complications.

Methods: Upright posterior-anterior chest radiographs of 94 postpneumonectomy patients were assessed for the rate of pleural fluid accumulation as a percentage of hemithorax volume.

Results: Overall median time to 70% hemithoracic opacification was 3 days and mean time was 27 days. The median time to 100% opacification was 66 days and mean time was 96 days.

Conclusion: The median time to 70% hemithoracic opacification postpneumonectomy is 3 days, while median time to 100% opacification was 66 days.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2014.11.001DOI Listing

Publication Analysis

Top Keywords

median time
16
fluid accumulation
12
opacification days
12
pleural fluid
8
time 70%
8
70% hemithoracic
8
hemithoracic opacification
8
days time
8
days median
8
time 100%
8

Similar Publications

Initial experience of a novel surgical assist robot "Saroa" featuring tactile feedback and a roll-clutch system in radical prostatectomy.

Sci Rep

December 2024

Department of Urology, The Jikei University School of Medicine, Kashiwa Hospital, Kashiwashita 163-1, Kashiwa, Chiba, 277-8567, Japan.

To evaluate the safety and efficacy of the Saroa Surgical Robot System in robot-assisted laparoscopic radical prostatectomy (RARP). We enrolled 60 patients who underwent RARP using either the Saroa (n = 9) or da Vinci Xi (n = 51) systems at Jikei University Kashiwa Hospital from January 2022 to March 2024. We compared preoperative characteristics, perioperative outcomes, complications, and postoperative urinary continence at three months between the two groups.

View Article and Find Full Text PDF

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).

Sci Rep

December 2024

Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and angioedema. Sacubitril/valsartan-associated ototoxicity is often underreported in clinical studies and real-world settings.

View Article and Find Full Text PDF

The Tibetan Plateau is home to numerous glaciers that are important for freshwater supply and climate regulation. These glaciers, which are highly sensitive to climatic variations, serve as vital indicators of climate change. Understanding glacier-fed hydrological systems is essential for predicting water availability and formulating climate adaptation strategies.

View Article and Find Full Text PDF

Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay.

J Antimicrob Chemother

December 2024

Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.

Background: Our research aimed to investigate the potential of in vitro triple antimicrobial synergism against carbapenem-resistant Pseudomonas aeruginosa (CRPA) as a strategy to overcome antimicrobial resistance.

Methods: We used 12 CRPA blood isolates stocked in the Asian Bacterial Bank between 2016 and 2018. All isolates were tested by multi-locus sequencing and carbapenemase multiplex PCR.

View Article and Find Full Text PDF

Refractory myasthenia gravis treated with autologous hematopoietic stem cell transplantation.

Ann Clin Transl Neurol

December 2024

Transplant and Cell Therapy Program, Division of Hematology, Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.

Objectives: Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment of MG is not broadly considered. Our objective is to report on the efficacy and safety of HSCT in refractory MG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!